Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
Capricor Therapeutics updates stakeholders on the upcoming FDA advisory committee review of its Biologics License Application for Deramiocel, a cell therapy targeting Duchenne muscular dystrophy. The company highlights adherence to its final analysis plan and disputes FDA briefing post-hoc analyses, emphasizing statistically significant results and…